Navigation Links
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
Date:8/30/2007

esting.

Phenoxodiol is being investigated as a therapy for late-stage, chemoresistant ovarian, prostate and cervical cancers. Phenoxodiol has received Fast Track status from the FDA to facilitate development as a therapy for recurrent ovarian and prostrate cancers.

Phenoxodiol is an investigational drug and, as such, is not commercially available. Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by FDA as being safe and effective for the intended use.

About Marshall Edwards Inc:

Marshall Edwards, Inc. (Nasdaq: MSHL) is a specialist oncology company focused on the clinical development of novel anti-cancer therapeutics. These derive from a flavonoid technology platform which has generated a number of novel compounds characterized by broad ranging efficacy against a range of cancer targets with few side effects. The unique combination of efficacy and safety has been explained by their ability to target an enzyme present on the surface of cancer cells, thereby inhibiting the production of pro-survival proteins within the cell. Marshall Edwards, Inc. has licensed rights from Novogen Limited (Nasdaq: NVGN) to bring three oncology drugs -- phenoxodiol, NV-196 and NV-143 -- to market globally. Marshall Edwards, Inc. is majority owned by Novogen, an Australian biotechnology company that is specializing in the development of therapeutics based on a flavonoid technology platform. Novogen, based in Sydney, Austra
'/>"/>

SOURCE Marshall Edwards Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 Greenway ... flagship integrated EHR, Prime Suite (®) ... Certified(®) 2011 Ambulatory EHR, additionally certified for ... Advanced Reporting. Greenway,s Prime Suite 2011 ... 2011 certification designations offered by the Certification ...
(Date:12/14/2009)... WASHINGTON, Dec. 14 Gibraltar Associates, ... on global and domestic communications and issues ... an agreement with PositiveID Corporation (Nasdaq: ... public relations agency of record. Gibraltar Associates ... communications and advise the Company on its ...
(Date:12/14/2009)... 14 Cardium Therapeutics (NYSE Amex: ... Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment of ... Science and Industry Conference held December 10-13, 2009 ... conference is attended by top industry leaders and ... healing. Dr. Barbara K. Sosnowski, Cardium,s Vice ...
Breaking Medicine Technology:Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 2Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 3Greenway Medical Technologies' PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification 4Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 1Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 2Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 3Photos 3A Compete Releases Top Insurance and Physician Web Sites for June 2009 52976 4Established Medical Sub Component Manufacturer Achieves ISO 13485 Certification 52972 1Established Medical Sub Component Manufacturer Achieves ISO 13485 Certification 52972 2Established Medical Sub Component Manufacturer Achieves ISO 13485 Certification 52972 3Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 1Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 2Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 3Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 4
... 19 New research published in the,British ... 17, PMID: 18081945, 2007),shows that blueberries may ... Lead scientist, Wilhelmina Kalt, Ph.D,from Agriculture and ... a,blueberry-supplemented diet. Blueberry-supplemented diets resulted in a,reduction ...
... is first to show safety and effectiveness of using cloned cells alone ... ... Researchers describe the first,successful use of a human patient,s cloned infection-fighting T ... A team led by Cassian Yee, M.D., an associate member of the,Clinical ...
Other Medicine Technology:Blueberry-Supplemented Diet Shows Promise in Lowering Cholesterol in Animal Trials 2Patient's Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation 2Patient's Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation 3
(Date:12/14/2009)... 29 year-old mother from Phoenix who lost 120 pounds (half ... Dr. Siegal,s COOKIE DIET® six-cookies-a-day weight-loss program and foods, appeared ... Today Show. The Joy Fit Club feature, hosted by nutritionist ... those who have lost at least 100 pounds. Raper lost ... two years. ,, "The first time I met Dr. Siegal ...
(Date:12/14/2009)... A new study published by researchers from the University ... Fla., has found that cancer patients with dementia have ... alone, even after controlling for factors such as age, ... published in the early online edition of the journal ... a diagnosis of dementia shouldn,t discourage the use of ...
(Date:12/14/2009)... number of medication-related problems, including under treatment, suboptimal drugs, ... on their quality of life. Now new research (1), ... University of North Carolina at Chapel Hill shows that ... to medical regimens is a particular issue for this ... racial disparities in the quality of medication use appears ...
(Date:12/14/2009)... Recycled Tyvek clothing supplier, MPE, offers protective garments online to ... ... Hammond, Ind. (PRWEB) December 14, 2009 -- ... protective garments , announces its recent approval as a ... As an approved DOD EMALL vendor, MPE can provide military, ...
(Date:12/14/2009)... seen for ,standard-of-care, breast cancer treatment, study finds , , ... finds a significant racial disparity in breast cancer treatment: ... to receive radiation therapy after a lumpectomy. , ... the treatment of breast cancer that is caught in ... the Dec. 14 issue of the journal Cancer ...
Breaking Medicine News(10 mins):Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 3Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 4Health News:Study finds significantly worse outcomes in cancer patients with cognitive impairment 2Health News:Study finds significantly worse outcomes in cancer patients with cognitive impairment 3Health News:Racial differences in medication use 2Health News:MPE Inc., a Leading Supplier of Recycled Protective Garments, Becomes Approved Vendor on DOD EMALL 2Health News:After Lumpectomy, Radiation Rates Lower for Black Women 2
... to an imaginary friend rather than a real one need not ... pal can have a positive effect on children. ,Karen ... also insists that imaginary friends are not a sign that your ... her age group, but a sign that your child has an ...
... 2,200 women at the Kimmel Cancer Center at Jefferson in ... cancer at the time of diagnosis than Caucasian women. ... have breast cancer tumour types that are more aggressive and ... line with other recent studies and provide more powerful evidence ...
... about an obesity drug, orlistat (Xenical or Alli) that was ... ,The drug binds and interacts with a protein found ... cell death. ,The study was conducted by a ... at Wake Forest University School of Medicine. ,As ...
... also serve to repress an alcoholic's desire for drink, ... University of California-San Francisco . ,Varenicline, manufactured ... in the United States and Europe in 2006, has ... brain's reward system for addictive substances. ,The ...
... and Microsoft, aware that a large number of Internet ... a presence in the healthcare sector . This, claims ... both healthcare professionals and medical device manufacturers. According to ... who are already having to come to terms with ...
... a skin-care product that would wipe away wrinkles and lighten ... government's team of camel researchers, which has already pioneered such ... cosmetic properties in the hardy mammal's milk. ,"The ... hospital's skin department to study it on 20 people for ...
Other Medicine News:Health News:Afro- American Women Have More Aggressive Breast Cancer 2Health News:Afro- American Women Have More Aggressive Breast Cancer 3Health News:Battle Between Google and Microsoft Could Trigger Revolution in Healthcare 2
The complete performance package. Precision handling. Stable platform for device delivery. Enhanced backup support. Unique braid technology. Improved curve retention. Smooth PTFE liner....
The soft tip sheath design for smooth delivery and retrieval of Constellation advanced mapping basket catheters....
Fast-Cath, Maximum, Maximum Xtra, and Maximum ACT introducers represent the largest line of standard and specialty hemostasis introducers in the world....
A steerable diagnostic catheter with optimal maneuverability...
Medicine Products: